A Study of Combination Treatment With MabThera (Rituximab) and RoActemra (Tocilizumab) Versus RoActemra in Patients With Rheumatoid Arthritis With an Incomplete Response to Methotrexate

Stopped The study was terminated early because of a related decision to stop the development of ocrelizumab in rheumatoid arthritis.

Conditions

• Rheumatoid Arthritis

Interventions

• DRUG: Placebo
• DRUG: rituximab [MabThera/Rituxan]
• DRUG: tocilizumab [RoActemra/Actemra]

Sponsor

Hoffmann-La Roche